This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung epithelial cell line, in which the KANK2 gene has been disrupted to generate a loss-of-function model. The polyclonal population comprises a heterogeneous mixture of cells carrying diverse edits at the target locus, enabling robust experimental analysis without clonal expansion. Such polyclonal knockout cells are valuable for studying gene function in a bulk population, minimizing potential clonal artifacts.
The A-549 host cell line was established from the alveolar basal epithelial tissue of a 58-year-old Caucasian male with lung adenocarcinoma. These cells are widely employed as a model of human alveolar type II-like epithelial cells and are extensively used in lung cancer research, particularly for studying metastatic behavior, cellular adhesion, and cytoskeletal dynamics. A-549 cells form adherent monolayers and retain key epithelial characteristics, making them suitable for investigations of epithelial-mesenchymal transition and tumor cell motility.
KANK2 encodes an adaptor protein that serves as a critical node in the Integrin signaling and Rho GTPase pathways. It functions by linking integrin-mediated focal adhesions to the actin cytoskeleton and acts as a scaffold that recruits talin, liprin-beta1, and alpha-actinin to adhesion sites. KANK2 modulates RhoA activity, promoting RhoA inhibition downstream of integrin engagement, which leads to reduced actin polymerization and focal adhesion turnover. Additionally, it stabilizes cortical microtubules via interactions with tubulin, influencing cell polarity and directed migration. This protein is regulated by mechanical tension and Rho GTPase signals and acts downstream of integrin beta1 to orchestrate cytoskeletal reorganization.
In the A-549 lung adenocarcinoma model, disruption of KANK2 provides a powerful tool to dissect the mechanisms driving cancer cell migration and focal adhesion dynamics. Given KANK2’s role in suppressing RhoA activity, its loss is predicted to alter actin stress fibers and microtubule organization, potentially affecting metastatic potential. Furthermore, KANK2 mutations are associated with steroid-resistant nephrotic syndrome and podocyte dysfunction, so this A-549-based model also offers a simplified epithelial system to probe fundamental adhesion and cytoskeletal defects relevant to kidney biology, complementing podocyte-specific models.
This polyclonal knockout cell population is suitable for a wide range of functional assays, including Western blotting to assess KANK2 expression and downstream targets such as talin and RhoA, immunofluorescence staining of focal adhesions and actin filaments, quantitative cell migration and adhesion assays, and co-immunoprecipitation to examine interactions with talin and liprin-beta1. Additionally, RhoA activity assays (e.g., G-LISA) can be performed to directly measure GTPase signaling. These cells are particularly useful for researchers investigating integrin-mediated adhesion, cytoskeletal dynamics, cancer metastasis, and the molecular pathology of nephrotic syndrome. For additional information, please contact Ascent Research.
